SCHEMBL3556715

SCHEMBL3556715

COc1cc2c(O)cn(C(C)=O)c2cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 1/20 0.39
JAK2 O60674 1/20 0.39
MITF O75030 1/20 0.39
RAB9A P51151 1/20 0.39
PAX8 Q06710 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
PIM1 P11309 1/20 0.38
S1PR2 O95136 2/20 0.37
PLA2G2A P14555 1/20 0.37
KMO O15229 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MTNR1A P48039 3/20 0.36
MTNR1B P49286 2/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3558936 0.82 KMT2A (0.47) ALDH1A1NPC1JAK2MITFRAB9A
SCHEMBL3555777 0.79 NOTUM (0.36) NPC1RAB9APAX8NPSR1PIM1
SCHEMBL6037237 0.79 NOTUM (0.36) ALDH1A1NPC1RAB9APAX8NPSR1
SCHEMBL7893131 0.76 MTNR1A (0.58) NPSR1MEN1KMT2AMTNR1AMTNR1B
SCHEMBL7055812 0.75 MTNR1A (0.61) ALDH1A1SMN1; SMN2S1PR2MEN1KMT2A
SCHEMBL28693273 0.73 MTNR1A (0.49) ALDH1A1SMN1; SMN2NPC1RAB9AMTNR1A
SCHEMBL3560128 0.73 MTNR1A (0.59) ALDH1A1SMN1; SMN2NPC1RAB9APTGS1
SCHEMBL6436383 0.72 PTGS1 (0.47) ALDH1A1PTGS1PTGS2PLA2G2AKMO
SCHEMBL3554094 0.72 KMT2A (0.42) NPC1RAB9APAX8NPSR1KMO
SCHEMBL2475378 0.72 NOTUM (0.45) NPC1RAB9APAX8NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 US disclosed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP disclosed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed
WO-2004048331-A1 N-ARYLALKYL-3-AMINOALKOXYINDOLES AND THEIR USE AS 5-HT LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT ALDH1A1 1943/4885SMN1; SMN2 2700/4885NPC1 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.